JUNS · Jupiter Neurosciences, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Our management has concluded that our historical recurring losses from operations and negative cash flows from operations as well as our dependence on private equity and other financings raise substantial doubt about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to continue as a going concern in its audit report for the fiscal years ended December 31, 2025 and 2024.”View the 10-Q filed Aug 14, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Aug 7, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Aug 7, 2026.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JUNS
this stock
Jupiter Neurosciences, Inc.
|
$2.35M | — | — | — | 7.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Aug 7, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JUNS | -6.4% | -49.2% | — | -13.8% | — |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -5.3% | -47.4% | — | -13.5% | — |